Trial Profile
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC 698037) in Combination With Cisplatin (NSC 119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2018
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2014 Status changed from recruiting to discontinued, according to M.D. Anderson Cancer Center record.
- 09 Jun 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 28 Aug 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.